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EPSTEIN BARR VIRUS AND ITS ROLE ON BURKITT LYMPHOMA AND 
MULTIPLE SCLEROSIS 
For reactivation is necessary to replicate viral genomic
DNA and the synthesis of specific proteins for packing
the newly DNA into infectious virions.
Cytotoxic CD8+ T cells (CTL) are responsible for
elimination of proliferating and lytically infected B cells
causing symptomatology. CD4+ T cells and innate
immune response also take part in host defense.
However, EBV will remain again in latent memory B
cells that will return to the tonsils to have a massive
replication to go to the saliva to be transmitted.
Herpesvirus 4 (HSV-4), also known as Epstein Barr virus (EBV), is an
enveloped γ-herpesvirus which was discovered in 1964 by Anthony
Epstein in Burkitt lymphoma samples from children living in Uganda. It
has been classified as class I carcinogen virus by Agency for Research on
Cancer.
The virus contains 172kpb double strand DNA and it has tropism for B
lymphocytes where it is able to establish latency as an episome [Figure
1].
EBV was the first found encoding microRNAs (miRNAs) which can down-
regulate gene expression and inhibit the apoptotic response of the
infected cell. Furthermore, miRNAs can inhibit viral genes in order to
avoid immune response and establish a latent infection.
It also can drive B cells into continuous proliferation expressing:
Burkitt lymphoma (BL) is a neoplasic disease that affects human B lymphocytes and it is presented
multifocal, but it is found typically in the area of the jaw [Figure 3]. BL is not frequent and usually affects
to children aged 3-13 years with a peak of incidence at 6 years and it is more common in boys than girls. In
untreated cases it provokes death.
Multiple sclerosis (MS) is a chronic inflammatory
demyelinating disease of the Central Nervous System
(CNS) resulting in the formation of plaques. It causes
progressive disability and affects more than 2.5
million people of the world, particularly young
women.
EBV is the only agent infecting all MS patients and
the only one which infects and modulates B cells,
involved in the disease process. B cells from MS
patients expresses EBV latent proteins showing that
the virus displays the latency II transcription
program.
There are four hypothesis to explain how EBV could 
provoke MS:
 EBV is able to regulate the host immune response in lytic and latent
infections and remain invisible for long periods. That difficult the
control and possible eradication of this virus.
 EBV latent genes and miRNAs are essential for inducing B cells
proliferation and tumours generation.
 EBV infection is a prerequisite for the development of BL and MS but it
is not enough by itself to cause these diseases.
 The association between malaria, EBV infection and MYC translocation
is strongly related with BL development. The eradication of malaria
could decrease the incidence of BL.
 Controlling EBV infection could be important to decrease BL and MS
incidence.
 More studies with comparisons between EBV infection and other
viruses infections are needed to have convincing results.
 There is no vaccine to protect against EBV.
 There is no treatment for EBV but there are advices
for relieving symptoms in IM.
 In sporadic BL cases there is a treatment with
antineoplasic agents which produces an
improvement in 80% of cases.
 MS has no defined treatment but sunlight and
vitamin D protect against that disease.
Epstein Barr virus (EBV) is one of the most common human viruses (affecting 95% of world population) and normally, it causes asymptomatic infections. However, EBV can cause infectious mononucleosis (IM)
and other illnesses. It is known for its properties of causing deregulations of the host immune system and establishing latency in B lymphocytes.
Here, there is a compilation of results from diverse studies which debate the role of EBV in two diseases: Burkitt lymphoma and Multiple sclerosis, in order to comprehend its importance in these processes.
EBV is mainly transmitted by saliva but also
by other fluids contact.
In primary infection [Figure 2], the virus
enters in buccal cavity and contact with
naïve B cells in the tonsils through the
union of viral gp350 and CD21 expressed in
B cells. Then, a complex of viral
glicoproteins (gH, gL, gp42) binds to HLA
antigen class II to start the fusion of virus
envelope and B cell membrane which
produces an activation of B cells that
become proliferating B blasts.
B blasts enter the follicles where they
expand forming a germinal centre in which
follicular dendritic cells and specific CD4+ T
cells will check the ability of B cells to
receive signals from antigen.
The cells leave the follicle as infected
memory and latent B cells entering the
peripheral circulation. Some of these cells
will initiate replication of the virus to be
dropped into saliva.
EBV establishes latency in memory B cells
using only a limited number of genes to
maintain its genome and evade the host
immune reaction.
 Type III latency: EBV expresses all EBNA, LP, 3 LMPs
and EBER. This pattern is observed in IM and some
post-transplantant lymphoproliferative disorders
(PTLDs).
 Type II latency: EBNA1, LMP1, LMP2A and EBER
expressed. It is observed in classical Hodgkin
lymphoma and some PTLDs.
 Type I latency: Only EBNA1 and EBER are expressed.
It is common of Burkitt lymphoma.
 Type 0 or “true latency”: There is no viral gene
expression except during cell division. These cells are
not recognized by CTLs.
Unde r s t a nd i ng EBV  i n f e c t i o n
4. EBV-infected autoreactive B cell hypothesis
If after primary infection there is a defect in the
defense mechanism of the host, the number of
EBV infected B cells will not be controlled and
surviving autoreactive B cells could enter the CNS.
There, they could produce oligoclonal IgG and
pathogenic autoantibodies, which would attack
myelin and other components of the CNS.
Autoreactive T cells receive costimulatory signals
to destruct myelin and oligodendrocytes [Figure 4].
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Conc l u s i o n s
 Understand the switch from latency to lytic
replication cycle is a critical step in virus spreading.
Zta regulates this change and it is a possible target
for future vaccines.
1. EBV crossreactivity hypothesis
There is a crossreactivity between EBV and CNS
antigens, consequently, EBV specific CD8+ T cells
recognizes CNS antigens as EBV.
3. The αβ-crystallin or “mistaken self” hypothesis
The αβ-crystallin is a small heat-shock protein and
an immunodominant antigen of CNS that is
expressed in oligodendrocytes and myelin in early
MS lesions.
Peripheral EBV infection induces the expression of
this protein in HLA class II molecules in B cells.
Consecuently, CTLs are prepared against microbial
antigens and also to new expressed αβ-crystallin.
2. EBV bystander damage hypothesis
The immune system attacks EBV which is found in
CNS and it results in bystander damage to the CNS.
There are three types of BL: Endemic (or African) BL, related with the
presence of EBV; sporadic BL and immunodeficiency associated BL.
It is known that EBV can transform and drive B cells into unlimited
proliferation in vitro. It has been observed that most tumour cells from
endemic BL contains multiple EBV genomes and infectious virions can be
found in tumour cell lines.
EBV-BART-6-3p miRNA specially plays an important role in BL
pathogenesis, affecting the function of important signal transducers
involved in regulating the cell cycle.
Although EBV has these abilities, it is not enough to cause per se BL and
there are two possible cofactors that affect the regulation of apoptosis
in BL: Malaria and MYC translocation.
MYC TRANSLOCATION between the long arm of
chromosome 8 and chromosomes 14,2 or 22 is a
critical event in lymphoma’s formation.
MYC protein is a potent inducer of proliferation causing
apoptosis and its deregulation harm the
immunogenicity of human B cells.
EBV infected B cells present typical somatic
hypervariabe region mutations which suggests that
they have passed through the germinal centre where it
is found the activation-induced cytidine deaminase
(AID) gene, responsible for MYC translocation.
Endemic BL occurs in areas where MALARIA is
holoendemic whereas in places where malaria is
eradicated, the BL incidence has decreased. Possibly:
 Plasmodium falciparum would lead an increase of
EBV load because of the stimulation of the B cell
system and rising B cells pool that can be infected.
 P. falciparum antigens and other antigens reactivate
the virus from memory B cells increasing the viral
load.
Both agents cause B cell hyperplasia, an essential
component of lymphomagenesis in BL.
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Figure 1. a. EBV virion electron micrograph b.
Diagram showing the location of EBV latent genes
on the genome.
 Epstein-Barr nuclear antígens
(EBNA): EBNA1, EBNA2, EBNA3A,
EBNA3C
 Latent membrane proteins (LMP):
LMP1
 Small non-coding RNAs: EBER1,
EBER2
 miRNAs
Figure 2. Representation of EBV primary infection
Figure 3. Child with Burkitt lymphoma
typically located in the area of the jaw.
Figure 4. Role of EBV infection in the development of MS
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